Chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as a highly efficacious
treatment modality for refractory and relapsed hematopoietic malignancies in recent years …

Simple Summary A rapidly emerging new approach to treat cancer involves collection of
patient immune white blood cells and genetic re-programming of the cells to express a new …

Outcomes for half of patients with melanoma remain poor despite standard-of-care
checkpoint inhibitor therapies. The prevalence of the melanoma-associated antigen …

Simple Summary To study any disease, researchers need convenient and relevant disease
models. In cancer, the most commonly used models are two-dimensional (2D) culture …

The tumor microenvironment (TME) is shaped by dynamic metabolic and immune
interactions between precancerous and cancerous tumor cells and stromal cells like …

Sarcomas represent a distinct group of rare malignant tumors with high heterogeneity.
Limited options with clinical efficacy for the metastatic or local advanced sarcoma existed …

The successful treatment of patients affected by B-cell malignancies with Chimeric Antigen
Receptor (CAR)-T cells represented a breakthrough in the field of adoptive cell therapy …

Background Even acknowledging the game-changing results achieved in the treatment of
metastatic melanoma with the use of immune checkpoint inhibitors (ICI), a large proportion …

Gastrointestinal stromal tumors (GISTs) are rare, mesenchymal tumors of the gastrointestinal
tract, characterized by either KIT or PDGFRA mutation in about 85% of cases. KIT/PDGFRA …

T cells genetically engineered to recognize and eliminate tumor cells through synthetic
chimeric antigen receptors (CARs) have demonstrated remarkable clinical efficacy against B …